VEGFA and hereditary clear cell renal cell carcinoma: Similarly, nintedanib, a tyrosine kinase inhibitor that blocks the VEGF, FGF and PDGF pathways has been approved for non-small-cell lung cancer and recently for idiopathic pulmonary fibrosis [123,124,125], while pazopanib, a small molecule multi-kinase inhibitor that blocks VEGF, FGF, PDGF pathways and c-Kit and has been approved for advanced soft-tissue sarcoma and renal cell carcinoma [126].